Skip to main content

Multiple Sclerosis

Multiple sclerosis (MS) is the second-largest NLUTD population by volume. Approximately 75% of patients develop urinary symptoms during their disease course, most commonly OAB / detrusor overactivity early, evolving toward mixed patterns with impaired emptying and, in a minority, frank detrusor areflexia or DSD as spinal plaques accumulate.[1][3] The reconstructive urologist's role in MS is different from SCI: the lesions are disseminated and evolving, the phenotype can shift, and major reconstruction is uncommon — but botulinum, neuromodulation, and occasionally augmentation / diversion are all in play for the subset with refractory disease.

See Neurogenic Lower Urinary Tract Dysfunction for the general framework. For the procedural options that come into play in refractory MS, see Intradetrusor OnabotulinumtoxinA, Sacral Neuromodulation, Percutaneous Tibial Nerve Stimulation, Bladder Augmentation, and the Ileal Conduit.

Epidemiology and Natural History​

  • US prevalence ~1 million; more common in women (~3:1) and young adults.
  • ~75% of MS patients develop urinary symptoms over time; ~50% at presentation in some cohorts.[3]
  • OAB / DO is the most common finding (~60%), followed by detrusor underactivity / impaired emptying (~20%), DSD (~20–30% in spinal-predominant disease), and mixed patterns.
  • Urinary symptoms correlate with disability (EDSS score); they are rarely isolated — usually coexist with bowel, sexual, and mobility impairment.

Pathophysiology​

MS plaques disseminate in time and space. Urinary phenotype depends on the location of lesions, not on time since diagnosis:

  • Cortical / subcortical plaques → OAB / DO (uninhibited detrusor contractions).
  • Cervical / thoracic spinal plaques → DO + DSD (suprasacral phenotype; upper-tract risk if sustained high pressure).
  • Sacral cord / conus involvement may impair detrusor contraction. Cauda-equina disease is a peripheral lesion; do not automatically attribute it to MS without evaluating another cause.

Because lesions evolve, a patient's phenotype can shift — e.g., from pure OAB to OAB + incomplete emptying — requiring re-evaluation when symptoms change.

Evaluation​

Initial workup is the AUA/SUFU framework.[1] Most MS patients are unknown-risk at entry and should have baseline:

  • History + focused neurologic exam (EDSS, mobility, dexterity, cognition)
  • Voiding diary + UA + PVR
  • Renal ultrasound and eGFR
  • Multichannel urodynamics to complete unknown-risk classification

Additional reasons to reassess with multichannel urodynamics:

  • Refractory symptoms despite empirical therapy
  • Elevated PVR suggesting DSD or underactivity
  • Upper-tract deterioration
  • Before botulinum injection, SNM, or reconstructive surgery
  • Recurrent febrile UTI

Video-urodynamics specifically documents DSD and VUR, both of which change management.

Unknown-risk is not low-risk. Under AUA/SUFU, complete renal assessment, upper-tract imaging and multichannel urodynamics to establish risk in an unknown-risk patient; mild symptoms alone do not establish safe storage.[1]

Management​

Behavioral and pharmacologic first line​

  • Fluid management (avoid late-evening intake for nocturia).
  • Bowel regimen — MS constipation is common and worsens urinary symptoms.
  • Pelvic-floor muscle training — modest benefit in MS.
  • Antimuscarinics — first-line for OAB. Trospium (minimal CNS penetration) is often preferred in MS given cognitive risk.
  • β3-adrenergic agonists (mirabegron, vibegron) — first-line alternative when anticholinergic side effects are limiting; often preferred in progressive MS with cognitive concerns.
  • Combination therapy when monotherapy inadequate.
  • Desmopressin — selected nocturnal-polyuria cases after renal, sodium and fluid-intake assessment; older age raises hyponatremia risk. Use the drug-specific safety and monitoring guidance.
  • α-blockers — may improve voiding parameters in selected patients who spontaneously void; they are not a substitute for safe drainage.[2]

Catheterization​

  • CIC — consider for clinically important incomplete emptying, unsafe voiding or an agreed continence plan. A single PVR >100 mL or DSD label alone is not a universal indication; consider capacity, repeat volumes, symptoms, infections and pressures. Many MS patients retain sufficient hand function for CIC well into the disease; visual and cognitive issues are commoner obstacles than motor.
  • Indwelling SPC — when dexterity, spasticity, or caregiver support preclude CIC; preferable to urethral catheter in men and in women with progressive disability.
  • Intermittent versus indwelling drainage — assess ability, caregiver support, complications and treatment burden. CIC may be assisted and does not guarantee freedom from infection; SPC is an option when the intermittent regimen is not feasible.[5]

Intradetrusor onabotulinumtoxinA​

For refractory adult detrusor overactivity associated with MS, the US NDO dose is 200 U; the 100-U idiopathic OAB regimen is a different indication. Assess retention risk and ensure a feasible catheterization plan if needed. Retreat according to response and the label’s minimum interval, not an automatic calendar. See indications, dosing and follow-up.[2]

Sacral neuromodulation (SNM)​

  • Reasonable in MS with refractory OAB or non-obstructive retention.[2]
  • Test phase before permanent implant; MS lesions can complicate response.
  • MRI compatibility — critical consideration because MS patients require periodic MRI surveillance. Newer SNM devices are MRI-conditional.

Percutaneous tibial nerve stimulation (PTNS)​

An option for selected neurogenic storage symptoms. Evidence does not establish a universal durability ranking against SNM in MS.[5]

Surgical reconstruction​

  • Augmentation cystoplasty — rare in MS; consider for refractory DO or poor compliance after less-invasive therapy; SNM failure and established upper-tract injury are not mandatory prerequisites.[2]
  • Continent catheterizable channel (Mitrofanoff) — occasionally constructed when hand dexterity for urethral CIC fails but abdominal-wall access is still feasible.
  • Ileal conduit — for patients with severe disability, no practical CIC option, and refractory incontinence. Selection depends on the individual’s disease trajectory, goals and ability to sustain bladder care; MS diagnosis alone does not establish a lower surgical threshold.

Special Considerations in MS​

MRI and device selection​

MS patients typically need recurrent brain and spinal-cord MRIs for disease surveillance. Always verify device MRI compatibility before permanent implants (for example, SNM or AUS).

Disease-modifying therapy and perioperative planning​

  • Many MS patients are on immunomodulators (interferons, natalizumab, fingolimod, ocrelizumab). Coordinate medication-specific perioperative decisions with the MS neurologist, considering infection, immune status and relapse/rebound risk; do not use a blanket stop-or-continue rule.
  • Steroid courses for MS relapses increase short-term UTI risk.

Progressive disease and advance care planning​

Urologic management evolves as disability progresses. Discuss future options before an acute deterioration; botulinum, catheter drainage and reconstruction are individualized choices rather than a mandatory sequence.

UTI in MS​

  • Incidence of symptomatic UTI is higher in MS, especially in those on CIC or with high PVR.
  • Infection can cause a pseudo-relapse (temporary worsening without new inflammatory activity). Evaluate infection and neurological change rather than automatically labeling deterioration a true MS relapse; treat symptomatic infection and avoid treating asymptomatic bacteriuria.[4]

Sexual Function​

  • ~50% of women and ~70% of men with MS report sexual dysfunction.
  • Women: reduced lubrication, anorgasmia, genital sensory changes.
  • Men: erectile dysfunction → PDE5i first-line; intracavernosal injection or prosthesis in refractory cases.
  • Ejaculatory dysfunction is common; fertility workup as indicated.

Clinical Correlations for the Reconstructive Urologist​

  • Symptoms change with disease. Reassess any MS patient whose urinary pattern shifts; a previously effective regimen can become inadequate with new spinal plaques.
  • MRI compatibility drives device choice. SNM MRI-conditional models, AUS, and any implant require verification against the patient's MS-surveillance MRI protocol.
  • Cognitive load of medications matters. Prefer β3 agonists and trospium over other anticholinergics in MS with cognitive symptoms.
  • Aggressive early management pays off. Empiric behavioral + pharmacologic therapy resolves most early MS urinary symptoms; complete risk assessment in unknown-risk disease rather than waiting for treatment failure or renal injury.
  • Multidisciplinary team. MS neurologist, urologist, pelvic-floor PT, incontinence / continent-catheter nurse educator, mental health support for the sexual-function domain.

See Also​

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

2. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

3. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

4. National Multiple Sclerosis Society. Urinary Dysfunction and MS, infection and pseudo-exacerbation. Accessed September 11, 2026.

5. Panicker JN, Fanciulli A, Skoric MK, et al. NEUROGED Guidelines. Eur J Neurol. 2025. doi:10.1111/ene.70119. Full text.